Adenosine Administration for Supraventricular Tachycardia

Administration Protocol

• Adenosine should be administered via a large proximal vein as a rapid IV push followed immediately by a 20 mL saline flush, according to the American Heart Association, with an initial dose of 6 mg IV push 1
• If rhythm does not convert within 1-2 minutes, administer 12 mg IV push, as recommended by the American Heart Association 1
• A defibrillator should be available when administering adenosine to any patient in whom Wolff-Parkinson-White syndrome is a consideration, due to the possibility of initiating atrial fibrillation with rapid ventricular rates, as advised by the American Heart Association 1

Special Considerations

• Larger doses may be required for patients with significant blood levels of theophylline, caffeine, or theobromine, according to the American Heart Association 1
• Reduce the initial dose to 3 mg in patients taking dipyridamole or carbamazepine, those with transplanted hearts, or if given by central venous access, as recommended by the American Heart Association 1
• Adenosine is safe and effective during pregnancy, according to the American Heart Association 1
• Adenosine should not be given to patients with asthma due to risk of bronchospasm, as warned by the American Heart Association 1

Post-Conversion Management

• Monitor the patient for recurrence after conversion, as advised by the American Heart Association 1
• Treat any recurrence with adenosine or consider a longer-acting AV nodal blocking agent, such as diltiazem or β-blocker, according to the American Heart Association 1
• If adenosine reveals another form of SVT, consider treatment with a longer-acting AV nodal blocking agent, as recommended by the American Heart Association 1

Common Side Effects

• Most common side effects include flushing, dyspnea, and chest discomfort, as reported by the American Heart Association 1

Adenosine Therapy for Supraventricular Tachycardia

Initial Assessment and Management

• The American Heart Association recommends vagal maneuvers as the first-line intervention for hemodynamically stable patients with regular SVT, followed by adenosine if vagal maneuvers fail, with success rates of 78-96% in terminating AVNRT and AVRT 2, 3
• For hemodynamically unstable SVT, synchronized cardioversion is indicated, though adenosine should be considered first if the tachycardia is regular with narrow QRS complex 4, 5

Adenosine Administration

• Adenosine should be administered via proximal IV as a rapid bolus followed by saline flush, with an initial dose of 6 mg IV push, followed by up to two additional 12 mg boluses if necessary at 1-2 minute intervals 2, 4, 6
• Continuous ECG recording during administration helps diagnostically and distinguishes between drug failure and successful termination with immediate reinitiation 2, 4

Mechanism and Effectiveness

• Adenosine is highly effective in terminating SVTs that involve the AV node in the reentrant circuit, with success rates of 78-96% 2, 4
• Adenosine terminates approximately 95% of AVNRT cases, according to the American College of Cardiology 7, 8

Diagnostic Value

• Adenosine serves as both therapeutic and diagnostic agent for narrow-complex tachyarrhythmias, and can unmask atrial flutter or atrial tachycardia 2, 3, 4, 7, 8

Special Considerations

• The American Heart Association recommends adenosine as a safe and effective treatment for SVT in pregnancy 6
• Larger doses of adenosine may be required for patients with significant blood levels of certain medications, such as theophylline or caffeine 6

Dosis Awal Adenosin untuk SVT

Protokol Pemberian yang Benar

• The American College of Cardiology/American Heart Association/Heart Rhythm Society recommends starting with adenosin 6 mg as the initial dose, not 12 mg, for the treatment of supraventricular tachycardia (SVT) in patients, with a dosing protocol that includes a 6 mg IV bolus followed by a saline flush, and subsequent doses of 12 mg if necessary 9, 10
• The initial dose of 6 mg IV bolus should be administered rapidly through a proximal vein, followed immediately by a 20 ml saline flush, with subsequent doses of 12 mg given if conversion does not occur within 1-2 minutes 9, 10
• The maximum total safe dose reported is up to 24 mg, with the dosing protocol allowing for repeated administration of 12 mg doses if necessary 10

Mengapa Tidak Langsung 12 mg?

• The American College of Cardiology/American Heart Association/Heart Rhythm Society recommends starting with 6 mg due to the dose-dependent nature of adenosin's side effects, which are generally transient but can be significant, and the fact that 70% of patients can be converted with 6 mg or less 9, 11
• The side effects of adenosin are dose-dependent and can include flushing, chest pain, and shortness of breath, but are typically short-lived, lasting less than 60 seconds 9, 11

Pertimbangan Khusus untuk Dosis

• The dose of adenosin should be increased in patients who consume significant amounts of theophylline, caffeine, or theobromine, as these substances can reduce the effectiveness of adenosin 9
• Patients with certain conditions, such as those taking dipyridamole or carbamazepine, or those with a heart transplant, may require a reduced initial dose of 3 mg, while patients with central venous access may require a higher dose due to reduced bioavailability 9

Kontraindikasi

• Adenosin is contraindicated in patients with certain conditions, including AV block degree 2 or 3, sick sinus syndrome, and bronchospastic or bronchoconstrictive lung disease, such as asthma, due to the risk of exacerbating these conditions 11

Post-Adenosine Conversion Management for SVT

Immediate Post-Conversion Monitoring

• Continuous cardiac monitoring is essential immediately after conversion because patients commonly experience atrial or ventricular premature complexes that may trigger recurrent episodes of SVT, and watch for immediate reinitiation of tachycardia, which can occur within seconds to minutes of successful conversion, according to the American Heart Association 12
• Premature complexes post-conversion are triggers for recurrence, and consideration of prophylactic AV nodal blockade in high-risk patients is recommended, as suggested by the American College of Cardiology 12

Treatment of Recurrent SVT

• An antiarrhythmic drug may be required to prevent acute reinitiation of tachycardia in patients who demonstrate immediate recurrence after conversion, whether from adenosine or cardioversion, particularly in patients with frequent premature complexes immediately post-conversion, as recommended by the American Heart Association 12

Adenosine for Supraventricular Tachycardia

Introduction to Adenosine Therapy

• The American Heart Association recommends adenosine as the first-line pharmacologic agent for acute treatment of regular SVT in hemodynamically stable patients, administered as 6 mg rapid IV push followed by 12 mg doses if needed, but is absolutely contraindicated in patients with asthma due to risk of severe bronchospasm 13, 14

Efficacy of Adenosine

• Adenosine has a success rate of 90-95% for AVNRT and 78-96% for AVRT, when administered to patients with stable blood pressure and regular SVT 15

Alternative Agents

• For patients with asthma or COPD and stable SVT, the American College of Cardiology recommends IV diltiazem 15-20 mg over 2 minutes (64-98% conversion rate) 13
• For patients with asthma or COPD and stable SVT, IV verapamil 2.5-5 mg over 2 minutes is also recommended 13
• For patients with asthma or COPD and stable SVT, IV beta-blockers may be used, though with caution in severe COPD 13, 14

Management of Hemodynamically Unstable Patients

• The American Heart Association recommends proceeding directly to synchronized cardioversion if patient shows hypotension, altered mental status, signs of shock, chest pain, or acute heart failure 13, 14
• Adenosine may still be considered first if tachycardia is regular with narrow QRS complex in hemodynamically unstable patients 13

Treatment After SVT Converts to Normal Rhythm

Immediate Post-Conversion Management

• The American College of Cardiology recommends that after successful conversion of SVT to normal sinus rhythm, the primary focus shifts to preventing recurrence through either catheter ablation or long-term pharmacologic therapy, with immediate post-conversion monitoring for recurrence being critical in the acute setting 16

Long-Term Management Strategy

First-Line: Catheter Ablation

• Catheter ablation should be considered as first-line therapy for preventing recurrent SVT, as it is the most effective, safe, and cost-effective approach 16
• The American College of Cardiology/American Heart Association/Heart Rhythm Society guidelines favor catheter ablation over medical therapy as the more cost-effective approach 16

Alternative: Long-Term Pharmacologic Therapy

• Oral beta-blockers, diltiazem, or verapamil are reasonable options for long-term prevention of AVNRT 17

Critical Decision Points

Shared Decision-Making

• Include the patient in clinical decision-making, considering their preferences, goals for therapy, and unique physical, psychological, and social situation 16

Patient Education on Self-Management

• Teach vagal maneuvers (modified Valsalva maneuver, carotid massage, ice-water facial immersion) for self-termination of future episodes 17, 18
• Consider "pill-in-the-pocket" therapy as a personalized, self-directed intervention developed in partnership with the patient 16

Acute Management of Supraventricular Tachycardia

1. Immediate Assessment of Hemodynamic Stability

• In patients presenting with hypotension, altered mental status, shock, chest pain, or acute heart failure, proceed directly to synchronized cardioversion without attempting pharmacologic therapy; this restores sinus rhythm in virtually all hemodynamically unstable cases. [**American College of Cardiology**] [19, 20, 21]

2. First‑Line Therapy for Hemodynamically Stable Patients – Vagal Maneuvers

• Vagal maneuvers are the recommended initial intervention before any drug administration. [**American College of Cardiology**] [19, 20]
• Modified Valsalva maneuver: patient performs a forced exhalation against a closed airway for 10–30 seconds (≈30–40 mm Hg intrathoracic pressure) while supine. [**American College of Cardiology**] [19]
• Carotid sinus massage: apply steady pressure over the carotid sinus for 5–10 seconds after confirming absence of a bruit. [**American College of Cardiology**] [19]
• Ice‑water facial immersion: place an ice‑cold wet towel on the face. [**American College of Cardiology**] [19]
• Overall success rate of vagal maneuvers in terminating SVT is ≈ 27 % across adult populations. [**American College of Cardiology**] [19]
• Critical safety pitfall: never apply pressure to the eyeball. [**American College of Cardiology**] [19]

3. Adenosine as the Preferred Pharmacologic Agent (When Vagal Maneuvers Fail)

• Adenosine is the first‑line drug for acute SVT termination, achieving conversion in 90–95 % of AV nodal re‑entrant tachycardia (AVNRT) and 78–96 % of atrioventricular re‑entrant tachycardia (AVRT). [**American College of Cardiology**] [19]

4. Alternative Pharmacologic Options (Adenosine Contraindicated or Unsuccessful)

• Calcium‑channel blockers (preferred alternatives):
  
  • Intravenous diltiazem 15–20 mg administered over 2 minutes converts SVT in 64–98 % of cases and is especially effective for AVNRT. [**American College of Cardiology**] [19]
  • Intravenous verapamil 2.5–5 mg over 2 minutes may also be used. [**American College of Cardiology**] [19]
• Beta‑blockers:
  
  • Intravenous esmolol is useful for short‑term SVT control, particularly when concurrent hypertension is present. [**European Society of Cardiology**] [20]
  • Intravenous metoprolol is an acceptable alternative. [**American College of Cardiology**] [19]
• Safety warnings for calcium‑channel blockers: do not administer verapamil or diltiazem if:
  
  • Ventricular tachycardia cannot be excluded;
  • Pre‑excited atrial fibrillation (e.g., Wolff‑Parkinson‑White) is present, due to risk of ventricular fibrillation;
  • Suspected systolic heart failure exists. [**American College of Cardiology**] [19]

5. Synchronized Cardioversion for Pharmacologic‑Resistant or Contraindicated Cases

• In hemodynamically stable patients where drugs are ineffective or contraindicated, elective synchronized cardioversion is highly effective, achieving near‑100 % termination of SVT (AVRT and AVNRT). [**American College of Cardiology**, **American Heart Association**] [19, 21]

6. Special Populations

• Pregnancy:
  
  • Vagal maneuvers remain the first‑line approach. [**American Heart Association**] [21]
  • If the patient becomes hemodynamically unstable, electrical cardioversion is indicated. [**American Heart Association**] [21]
• Adult Congenital Heart Disease (ACHD):
  
  • Acute antithrombotic therapy is recommended for atrial tachycardia or atrial flutter, following atrial fibrillation guidelines. [**American Heart Association**] [21]
  • Intravenous adenosine is appropriate for SVT termination. [**American Heart Association**] [21]
  • Intravenous diltiazem or esmolol may be used cautiously, monitoring for hypotension. [**American Heart Association**] [21]
  • Flecainide should be avoided in the presence of significant ventricular dysfunction. [**American Heart Association**] [21]

7. Diagnostic Considerations During Acute Management

• A 12‑lead ECG must be obtained while the tachycardia is ongoing to differentiate SVT mechanisms and exclude ventricular tachycardia or pre‑excited atrial fibrillation. [**American College of Cardiology**] [19]
• Administration of adenosine can unmask underlying atrial flutter or atrial tachycardia, aiding diagnosis. [**American College of Cardiology**] [19]

Acute Management of Hemodynamically Stable Supraventricular Tachycardia

Initial Non‑Pharmacologic Management

• The American College of Cardiology recommends that vagal maneuvers be attempted first in all hemodynamically stable patients with SVT. 22, 23
• A modified Valsalva maneuver (patient supine, bearing down for 10–30 s to generate ≥30–40 mm Hg intrathoracic pressure) achieves conversion in roughly 43 % of attempts. 22
• Across all vagal techniques, the overall success rate is approximately 27.7 %. 22

First‑Line Pharmacologic Therapy (Adenosine)

• Adenosine is the first‑line drug for acute treatment of hemodynamically stable SVT in adults without contraindications; the standard initial dose is 6 mg rapid IV push followed immediately by a 20 mL saline flush. 22, 23
• Adenosine terminates 90–95 % of AVNRT and 78–96 % of AVRT episodes, making it the most effective first‑line agent. 22, 23
• If conversion does not occur within 1–2 minutes, a second dose of 12 mg IV push with saline flush is recommended. 22
• A third dose of 12 mg may be given if the rhythm remains unchanged after the second dose. 22

Alternative Pharmacologic Options (When Adenosine Is Contraindicated)

• Intravenous diltiazem is the preferred alternative for patients with asthma or COPD, achieving conversion in 64–98 % of cases. 22, 23
• Diltiazem dosing: 15–20 mg (≈0.25 mg/kg) IV administered over 2 minutes. 22
• Verapamil (2.5–5 mg IV over 2 minutes) is an acceptable alternative calcium‑channel blocker. 22
• Intravenous β‑blockers (metoprolol or esmolol) may be used with caution in severe COPD; they are slightly less effective than calcium‑channel blockers. 22, 23
• The American College of Cardiology advises against administering verapamil or diltiazem when any of the following are present: (1) ventricular tachycardia cannot be excluded, (2) pre‑excited atrial fibrillation (e.g., WPW syndrome), (3) suspected systolic heart failure, or (4) hemodynamic instability. 22

Immediate Cardioversion for Unstable SVT

• Synchronized cardioversion should be performed without preceding vagal maneuvers or medication when the patient exhibits hypotension, altered mental status, shock, chest pain, or acute heart failure. 22, 23
• In hemodynamically unstable SVT, synchronized cardioversion achieves near‑100 % termination. 22, 23

Post‑Conversion Management

• If adenosine reveals an alternative SVT mechanism (e.g., atrial flutter or atrial tachycardia), a longer‑acting AV‑nodal blocking agent such as diltiazem or a β‑blocker should be considered for ongoing rhythm control. 22

Maximum Recommended Adenosine Dose and Administration for Paroxysmal Supraventricular Tachycardia (PSVT)

Maximum Cumulative Dose

• The American College of Cardiology/American Heart Association/Heart Rhythm Society (ACC/AHA/HRS) guidelines state that the maximum cumulative dose of adenosine for acute termination of PSVT in adults is 30 mg total (6 mg + 12 mg + 12 mg); single bolus doses of 18 mg have been reported as safe in clinical practice【24】【25】.

Standard Dosing Protocol

• Initial dose: 6 mg rapid IV bolus administered over 1–2 seconds through a large proximal vein, immediately followed by a 20 mL saline flush【24】【25】.
• Second dose: If conversion does not occur within 1–2 minutes, give a 12 mg rapid IV bolus with saline flush【24】【25】.
• Third dose: If still no response, an additional 12 mg rapid IV bolus may be administered【24】【25】.
• Maximum cumulative dose: The sequence above yields a total of 30 mg (6 mg + 12 mg + 12 mg)【24】【25】.

Higher‑Dose Considerations

• The ACC/AHA/HRS guidelines note that single 18‑mg bolus doses have been used safely, particularly in patients with impaired venous return or those taking methylxanthines (e.g., theophylline, caffeine) who may require larger doses【24】【25】.

Absolute Contraindications

• Asthma or bronchospastic lung disease (risk of severe bronchospasm)【24】.
• Second‑ or third‑degree AV block or sick sinus syndrome without a pacemaker【24】【25】.

Administration Technique

Expected Response Timing

• The average time to termination after an effective adenosine dose is approximately 30 seconds; if no effect is observed within 1–2 minutes, the dose is considered insufficient and the next higher dose should be administered【24】【25】.

Management of Adenosine‑Refractory Paroxysmal Supraventricular Tachycardia

Second‑Line Pharmacologic Therapy

• When a rapid IV bolus of adenosine (6 mg followed by up to two 12 mg doses) does not terminate the tachycardia and the patient remains hemodynamically stable, the recommended next step is to give a longer‑acting AV‑nodal blocker—either intravenous diltiazem 15–20 mg administered over 2 minutes or intravenous metoprolol 2.5–5 mg every 2–5 minutes (up to a total of 15 mg over 10–15 minutes)—provided there are no contraindications such as heart failure, hypotension, or pre‑excited atrial fibrillation. 26

• Intravenous verapamil 2.5–5 mg given over 2 minutes is an acceptable alternative to diltiazem, with clinical effect typically observed within 3–5 minutes. 26

Safety Contraindications for Calcium‑Channel Blockers

• Calcium‑channel blockers must not be used if a wide‑complex tachycardia of uncertain origin (possible ventricular tachycardia) cannot be excluded, because AV‑nodal blockade may precipitate hemodynamic collapse. 26
• They must not be used in patients with pre‑excited atrial fibrillation (e.g., Wolff‑Parkinson‑White pattern), as AV‑nodal blockade can enhance accessory‑pathway conduction and trigger ventricular fibrillation. 26
• They must not be used in patients with suspected systolic heart failure or severe left‑ventricular dysfunction due to the risk of negative inotropic effects and cardiovascular collapse. 26

Beta‑Blocker Dosing Details

• Intravenous metoprolol should be administered in 2.5–5 mg increments every 2–5 minutes, with a maximum cumulative dose of 15 mg over 10–15 minutes, for patients in whom calcium‑channel blockers are contraindicated or not preferred. 27

Diagnostic Implications of a Failed Adenosine Test

• If adenosine administration fails to convert the rhythm but reveals an underlying atrial flutter or atrial tachycardia (by transient AV‑node block), the appropriate management shifts to rate control with a longer‑acting AV‑nodal blocker (diltiazem or a beta‑blocker) rather than attempting rhythm conversion. 26

Management of Suspected Pre‑Excited Atrioventricular Pathways (WPW)

• In patients in whom a pre‑excited atrial fibrillation or a wide‑complex tachycardia suggests Wolff‑Parkinson‑White syndrome, avoid adenosine, calcium‑channel blockers, beta‑blockers, and digoxin; instead, employ procainamide or proceed directly to synchronized cardioversion. 26

Strength of evidence: The cited sources do not specify a formal evidence grade; recommendations are based on expert consensus and observational data reported in the referenced publications.

Adenosine Dosing and Administration for Acute Supraventricular Tachycardia

Dosing Protocol

• The American College of Cardiology recommends an initial rapid IV bolus of 6 mg administered over 1–2 seconds, followed immediately by a 20 mL saline flush; if conversion does not occur within 1–2 minutes, a 12 mg dose should be given, and a second 12 mg dose may be repeated once more, with a maximum cumulative dose of 30 mg. 28

Administration Technique

• Use the most proximal peripheral IV access (e.g., antecubital vein) to ensure rapid delivery to the central circulation before metabolic degradation. 28
• Deliver adenosine as a rapid bolus over 1–2 seconds; a slower push is ineffective because the drug’s half‑life is <10 seconds. 28
• Follow the bolus immediately with a 20 mL saline flush to propel the medication into the central circulation. 28

Efficacy and Conversion Rates

• An initial 6 mg dose converts 70–80 % of paroxysmal SVT episodes caused by AVNRT or AVRT.
• Across all dosing steps, overall conversion rates are 90–95 % for AVNRT and 78–96 % for AVRT. 28

Dose Adjustments for Special Populations

Reduced Initial Dose (3 mg)

• Reduce the first dose to 3 mg in patients who are taking dipyridamole or carbamazepine, in cardiac transplant recipients (denervated hearts), or when the drug is administered via central venous access. 28

Increased Dose Requirements

• Consider higher doses in patients with significant blood levels of theophylline, caffeine, or theobromine, which act as competitive antagonists at adenosine receptors. 28

Absolute Contraindications

• Asthma or active bronchospasm – risk of severe bronchospasm.
• Second‑ or third‑degree AV block or sick‑sinus syndrome without a pacemaker.
• Pre‑excited atrial fibrillation (e.g., Wolff‑Parkinson‑White syndrome) – risk of rapid ventricular response and possible ventricular fibrillation. 28

Expected Response Timing

• The average time to termination of SVT after an effective adenosine dose is approximately 30 seconds.
• If no effect is observed within 1–2 minutes, the dose is considered insufficient and the next higher dose should be administered. 28

Adverse Effects (Transient, <60 seconds)

• Flushing (most common).
• Dyspnea.
• Chest discomfort or pain.
• Transient AV block.
• Premature ventricular contractions. 28

Management After Adenosine Administration

When Conversion Occurs

• Continue continuous ECG monitoring for early recurrence, as premature complexes can trigger repeat SVT episodes.
• If immediate recurrence occurs, administer a longer‑acting AV‑nodal blocker (e.g., diltiazem or a β‑blocker). 28

When Adenosine Fails to Convert

• Stable patients: give a longer‑acting AV‑nodal blocker – IV diltiazem 15–20 mg over 2 minutes (64–98 % conversion) or IV metoprolol 2.5–5 mg every 2–5 minutes (maximum 15 mg). 28
• Unstable patients: proceed immediately to synchronized cardioversion. 28

Management of Supraventricular Tachycardia with Aberrancy

Immediate Management of Hemodynamically Unstable Patients

Vagal Maneuvers in Hemodynamically Stable Patients

Adenosine as First‑Line Pharmacologic Agent

Alternative Pharmacologic Options (When Adenosine Fails or Is Contraindicated)

Synchronized Cardioversion for Drug‑Refractory or Contraindicated Cases (Stable Patients)

Diagnostic and Safety Considerations

Acute and Long‑Term Management of Supraventricular Tachycardia (SVT)

Immediate Assessment and Hemodynamic Decision‑Making

• In patients with hemodynamic instability (e.g., hypotension, altered mental status, shock, chest pain, or acute heart failure), immediate synchronized cardioversion after sedation should be performed; this restores sinus rhythm in ≈ 100 % of cases and pharmacologic therapy must not be attempted first. 32

Acute Pharmacologic Management for Hemodynamically Stable SVT

First‑Line Agent – Adenosine

• Adenosine terminates 90‑95 % of AV‑node re‑entrant tachycardia (AVNRT) episodes and 78‑96 % of atrioventricular re‑entrant tachycardia (AVRT) episodes. 32

Second‑Line – Calcium‑Channel Blockers (CCBs)

• Intravenous diltiazem is the preferred alternative when adenosine fails or is contraindicated (e.g., asthma), achieving a conversion rate of 64‑98 %. 32
• Recommended diltiazem dose: 15‑20 mg (≈0.25 mg/kg) given IV over 2 minutes; a slower infusion over up to 20 minutes reduces the risk of hypotension. 32
• Verapamil can be used as an alternative CCB: 2.5‑5 mg IV over 2 minutes, with clinical effect typically observed within 3‑5 minutes. 32
• Absolute contraindications for IV CCBs in SVT: (1) ventricular tachycardia cannot be excluded, (2) pre‑excited atrial fibrillation (e.g., Wolff‑Parkinson‑White), (3) suspected systolic heart failure, and (4) hemodynamic instability. 32

Third‑Line – Intravenous Beta‑Blockers

• Intravenous beta‑blockers are reasonable alternatives with an excellent safety profile, though they are slightly less effective than CCBs. 32
• Metoprolol dosing: 2.5‑5 mg IV every 2‑5 minutes; maximum cumulative dose 15 mg over 10‑15 minutes. 32
• Esmolol is useful for short‑term rate control, particularly when concurrent hypertension is present. 32
• Caution: use carefully in severe chronic obstructive pulmonary disease and avoid simultaneous IV administration of CCBs and beta‑blockers because of synergistic hypotensive and bradycardic effects. 32

Last‑Resort – Synchronized Cardioversion

• If all pharmacologic options fail or are contraindicated in a stable patient, synchronized cardioversion with appropriate sedation achieves successful conversion in 80‑98 % of cases. 32

Long‑Term Rhythm Control

First‑Line Oral AV‑Nodal Blockers

• Oral beta‑blockers, diltiazem, or verapamil are recommended for ongoing prevention of recurrent AVNRT. 32

Special Populations

Adult Congenital Heart Disease

• Adenosine remains appropriate for SVT termination in adults with congenital heart disease. 32
• Intravenous diltiazem or esmolol may be used cautiously, with close monitoring for hypotension. 32
• Flecainide should be avoided in the presence of significant ventricular dysfunction. 32

Critical Pitfalls to Avoid

• Do not delay cardioversion in hemodynamically unstable patients to attempt drug therapy.
• Do not administer calcium‑channel blockers when ventricular tachycardia or pre‑excited atrial fibrillation cannot be excluded, as this may precipitate ventricular fibrillation and death. 32
• Do not prescribe flecainide or propafenone to any patient with structural heart disease, ischemic heart disease, or left‑ventricular dysfunction.
• Do not combine IV calcium‑channel blockers with IV beta‑blockers because of the risk of severe hypotension and bradycardia.
• Do not use adenosine in patients with asthma due to the risk of severe bronchospasm.
• Do not employ eyeball pressure as a vagal maneuver; it is dangerous and no longer recommended. 32

Acute Assessment and Management of SVT Converting to Atrial Fibrillation and Sinus Tachycardia

Immediate Hemodynamic Assessment

• Assess for hypotension, altered mental status, chest pain, or signs of heart failure; if any are present, perform immediate synchronized cardioversion rather than pharmacologic therapy. (ACC/AHA) [33][34]

12‑Lead ECG Evaluation During Sinus Tachycardia

• Obtain a 12‑lead ECG to detect pre‑excitation (e.g., Wolff‑Parkinson‑White), structural heart disease, and P‑wave morphology that distinguishes true sinus rhythm from atrial tachycardia. (ACC/AHA) [33][35]36

Continuous Cardiac Monitoring

• Maintain continuous monitoring because premature atrial or ventricular complexes can trigger recurrent SVT or AF within seconds to minutes. (ACC/AHA) 34

Interpretation of Sinus Tachycardia

Physiologic Response

• Sinus tachycardia after the arrhythmic episode is often a normal autonomic response; confirm that the heart rate is appropriate for the clinical context before labeling it inappropriate. (ACC/AHA) 33

Possible Ongoing Atrial Tachycardia

• If P‑wave morphology differs from baseline sinus rhythm, consider focal atrial tachycardia rather than true sinus tachycardia. (ACC/AHA) [35][36]

Management of Physiologic Sinus Tachycardia

• Do not treat physiologic sinus tachycardia with AV‑nodal blockers.
• Investigate and correct secondary causes (e.g., hyperthyroidism, anemia, dehydration, pain, substance use) and manage anxiety; allow the rate to normalize as catecholamines clear. (ACC/AHA) 33

Monitoring for Recurrence

• Observe the patient for several hours for recurrence of SVT or AF, as the described pattern indicates electrical instability. (ACC/AHA) 34

Acute Management of Re‑occurring SVT

Vagal Maneuvers

• Perform a modified Valsalva maneuver (patient supine, 10–30 s strain); this terminates SVT in roughly 27–43 % of attempts. Do not apply pressure to the eyeball. (ACC/AHA) 33

Pre‑excitation (WPW) Warning

• If the baseline ECG shows pre‑excitation, adenosine may precipitate AF with rapid ventricular conduction; a defibrillator must be immediately available. (ACC/AHA) 34

Management of Atrial Fibrillation with Pre‑excitation

• Avoid adenosine, diltiazem, verapamil, β‑blockers, and digoxin because they can enhance accessory‑pathway conduction and precipitate ventricular fibrillation. (ACC/AHA) 34
• If the patient is hemodynamically unstable, proceed to synchronized cardioversion without delay. (ACC/AHA) 34
• If stable, administer IV procainamide or ibutilide to slow accessory‑pathway conduction and potentially terminate AF. (ACC/AHA) 34

Key Pitfalls to Avoid

• Do not assume sinus tachycardia requires pharmacologic treatment; it is usually self‑limited. (ACC/AHA) 33
• Do not give AV‑nodal blockers in the presence of pre‑excitation when AF develops, to prevent ventricular fibrillation. (ACC/AHA) 34
• Do not omit a 12‑lead ECG during each rhythm change, as it is essential for differentiating mechanisms, identifying pre‑excitation, and guiding therapy. (ACC/AHA) 35

Management of Supraventricular Tachycardia – Evidence‑Based Recommendations

Immediate Hemodynamic Assessment

• Hemodynamically unstable SVT (e.g., hypotension, altered mental status, signs of shock, acute heart failure) should be treated with immediate synchronized cardioversion after sedation, which restores sinus rhythm in nearly 100 % of cases【37】.
• Presence of shock (cold extremities, poor perfusion) or acute heart failure (pulmonary edema, severe dyspnea) defines instability and mandates direct cardioversion【37】.

Acute Management of Unstable SVT

• In any patient meeting the instability criteria, vagal maneuvers or pharmacologic therapy should be omitted and synchronized cardioversion performed without delay【37】.

Vagal Maneuvers (First‑Line for Stable SVT)

• Vagal techniques terminate SVT in approximately 27–43 % of episodes【37】.
• Modified Valsalva maneuver (patient supine, bearing down for 10–30 s to generate 30–40 mmHg intrathoracic pressure) is the most effective single maneuver with a 43 % success rate【37】.
• Carotid sinus massage may be used after confirming absence of carotid bruit and should be avoided in elderly patients or those with known carotid disease【37】.
• Ice‑water facial immersion (cold wet towel on the face) activates the diving reflex and can terminate SVT【37】.
• Application of pressure to the eyeball is prohibited because it is dangerous and has been abandoned【37】.

Adenosine (First‑Line Pharmacologic Agent)

• Adenosine terminates 90–95 % of AV‑node re‑entrant tachycardia (AVNRT) and 78–96 % of atrioventricular re‑entrant tachycardia (AVRT) episodes【37】.
• Dosing protocol: 6 mg rapid IV push (over 1–2 s) followed by a 20 mL saline flush; if no conversion in 1–2 min, give 12 mg rapid IV push with flush; a second 12 mg dose may be administered (maximum cumulative dose 30 mg)【37】.
• Reduce dose to 3 mg in patients receiving dipyridamole, carbamazepine, cardiac transplant recipients, or when administered via a central line【37】.
• Increase dose in patients with high caffeine, theophylline, or theobromine levels【37】.
• Absolute contraindications: active asthma/bronchospasm and second‑ or third‑degree AV block or sick‑sinus syndrome without a pacemaker【37】.
• Dyspnea occurs in roughly 30 % of administrations and resolves within 60 seconds【37】.
• A defibrillator must be immediately available because adenosine can precipitate rapid atrial fibrillation, especially in patients with Wolff‑Parkinson‑White syndrome【37】.

Calcium‑Channel Blockers or Beta‑Blockers (Second‑Line)

• Intravenous calcium‑channel blockers achieve 64–98 % conversion when adenosine fails or is contraindicated【37】.
• Preferred agent: diltiazem 15–20 mg (≈0.25 mg/kg) IV over 2 minutes; a slower infusion over 20 minutes reduces the risk of hypotension【37】.
• Alternative: verapamil 2.5–5 mg IV over 2 minutes, with clinical effect in 3–5 minutes【37】.
• Beta‑blocker options: metoprolol 2.5–5 mg IV every 2–5 minutes (max 15 mg over 10–15 minutes) or esmolol for short‑term control, particularly when hypertension coexists【37】.
• Absolute contraindications for calcium‑channel blockers: inability to exclude ventricular tachycardia, pre‑excited atrial fibrillation (WPW), suspected systolic heart failure, and any hemodynamic instability【37】.
• IV calcium‑channel blockers must never be combined with IV beta‑blockers because of synergistic hypotension and bradycardia【37】.

Synchronized Cardioversion (Rescue for Stable Patients)

• When all pharmacologic options fail or are contraindicated, elective synchronized cardioversion with appropriate sedation yields 80–98 % success in hemodynamically stable patients【37】.

Post‑Conversion Management

• Continuous cardiac monitoring is essential immediately after conversion, as premature atrial or ventricular complexes frequently trigger recurrent SVT within seconds to minutes【37】.
• If immediate recurrence occurs, administer a longer‑acting AV‑nodal blocker (e.g., diltiazem or a beta‑blocker) to prevent re‑initiation【37】.
• When adenosine unmasks atrial flutter or atrial tachycardia, manage with a longer‑acting AV‑nodal blocker for rate control rather than attempting rhythm conversion【37】.

Special Populations – Pregnancy

• Vagal maneuvers remain the first‑line therapy in pregnant patients【37】.
• Adenosine is considered safe and effective during pregnancy【37】.
• If the pregnant patient is hemodynamically unstable, synchronized cardioversion is indicated【37】.

Critical Pitfalls to Avoid

• Do not delay cardioversion in unstable patients to attempt vagal maneuvers or drug therapy【37】.
• Do not administer calcium‑channel blockers when ventricular tachycardia or pre‑excited atrial fibrillation is possible, as this may precipitate ventricular fibrillation and death【37】.
• Do not use adenosine in patients with asthma due to the risk of severe bronchospasm【37】.
• Do not apply pressure to the eyeball—this technique is hazardous and abandoned【37】.
• Always obtain a 12‑lead ECG during tachycardia to differentiate SVT from VT and to identify pre‑excitation【37】.

Long‑Term Management

• Catheter ablation should be offered as first‑line definitive therapy for all patients with symptomatic recurrent SVT; single‑procedure success rates range from 94.3 % to 98.5 % with low complication rates【37】.
• If ablation is declined or unsuitable, oral AV‑nodal blockers (beta‑blockers, diltiazem, or verapamil) are first‑line for prevention【37】.
• Flecainide or propafenone are 86–93 % effective at 12 months but are limited to patients without structural heart disease, ischemic heart disease, or left‑ventricular dysfunction; they are absolutely contraindicated in those conditions【37】.
• Patient education should include teaching self‑administered vagal maneuvers (modified Valsalva, appropriate carotid massage, facial cooling) for future episode termination【37】.

Immediate Management of Asymptomatic Tachycardia in Young Adults

Assessment of Hemodynamic Stability

• Signs of instability (altered mental status, chest pain, systolic BP < 90 mmHg, shock, acute heart failure) mandate immediate cardioversion rather than observation. 38, 39
• A systolic/diastolic pressure of 130/90 mmHg indicates hemodynamic stability, allowing diagnostic work‑up before any cardioversion. (American College of Cardiology) 40, 41

Diagnostic Evaluation

12‑Lead ECG During Tachycardia

• A 12‑lead ECG obtained while the heart rate is ~150 bpm is essential to differentiate supraventricular tachycardia (SVT) from sinus tachycardia, atrial flutter, atrial tachycardia, or ventricular tachycardia. (American College of Cardiology) 40, 41

ECG Features of Physiologic Sinus Tachycardia

• Gradual onset/offset, normal P‑wave morphology identical to baseline, and a heart‑rate response appropriate to the clinical context favor physiologic sinus tachycardia. (American College of Cardiology) 41

ECG Features of Paroxysmal SVT (PSVT)

• Abrupt onset, regular narrow‑complex tachycardia at 150–250 bpm, often asymptomatic, is characteristic of PSVT. (American College of Cardiology) 40, 41
• Absence of clear P waves or presence of retrograde P waves on a regular narrow‑complex rhythm confirms PSVT (AVNRT or AVRT). (American College of Cardiology) 40, 41

Acute Management

Vagal Maneuvers (First‑Line)

• Modified Valsalva maneuver (patient supine, bearing down 10–30 s to generate 30–40 mmHg intrathoracic pressure) terminates SVT in ≈ 43 % of attempts. (American College of Cardiology) 40, 41
• Carotid sinus massage (5–10 s steady pressure after confirming no carotid bruit) is an effective alternative vagal technique. (British Society of Sports Medicine) 38, 39, 40

Adenosine (First‑Line Pharmacologic Agent)

• Adenosine converts 90–95 % of AVNRT and 78–96 % of AVRT episodes, making it the definitive first‑line drug. (American College of Cardiology) 40, 41
• Dosing: 6 mg rapid IV push (1–2 s) followed by a 20 mL saline flush; if no conversion in 1–2 min, give 12 mg rapid IV push with flush; a second 12 mg dose may be given (max cumulative 30 mg). (American College of Cardiology) 40, 41
• Absolute contraindications: active asthma/bronchospasm, second‑ or third‑degree AV block, sick‑sinus syndrome without a pacemaker. (American College of Cardiology) 40, 41

Alternative Pharmacologic Options (If Adenosine Fails or Is Contraindicated)

• Intravenous diltiazem 15–20 mg over 2 min achieves 64–98 % conversion and is the preferred calcium‑channel blocker alternative. (American College of Cardiology) 40, 41
• Intravenous verapamil 2.5–5 mg over 2 min is an acceptable alternative calcium‑channel blocker. (British Society of Sports Medicine) 38, 39, 40, 41
• Intravenous β‑blockers (e.g., metoprolol 2.5–5 mg every 2–5 min, max 15 mg; or esmolol) are reasonable alternatives with an excellent safety profile. (American College of Cardiology) 40, 41
• Contraindications for calcium‑channel blockers: inability to exclude ventricular tachycardia, pre‑excited atrial fibrillation (WPW), suspected systolic heart failure, or hemodynamic instability. (American College of Cardiology) 40, 41

Synchronized Cardioversion (Rescue for Stable Patients)

• When pharmacologic therapy fails or is contraindicated, elective synchronized cardioversion with appropriate sedation yields 80–98 % success. (American College of Cardiology) 40, 41

Blood‑Pressure Management in the Acute Setting

• A BP of 130/90 mmHg in a 25‑year‑old meets ACC/AHA criteria for Stage 1 hypertension but does not require acute pharmacologic treatment. (ACC/AHA) 42
• After tachycardia resolution, arrange outpatient BP monitoring, lifestyle counseling (diet, exercise, weight loss, sodium restriction), and consider antihypertensive therapy only if repeat measurements remain elevated. (ACC/AHA) 42
• Initiate chronic antihypertensive therapy in the emergency department only if BP ≥ 180/120 mmHg or there is evidence of end‑organ damage. (ACC/AHA) 42

Post‑Conversion Management

• Continuous cardiac monitoring immediately after conversion is essential because premature atrial or ventricular complexes frequently trigger recurrent SVT within seconds to minutes. (American College of Cardiology) 40, 41
• If immediate recurrence occurs, administer a longer‑acting AV‑nodal blocker (e.g., oral diltiazem or a β‑blocker) to prevent re‑initiation. (American College of Cardiology) 40, 41
• Refer the patient to cardiology for consideration of catheter ablation (94–98 % single‑procedure success) or long‑term pharmacologic prophylaxis if episodes are recurrent. (American College of Cardiology) 40, 41

Safety Pitfalls to Avoid

• Do not administer calcium‑channel blockers when ventricular tachycardia or pre‑excited atrial fibrillation is possible, as this may precipitate ventricular fibrillation. (American College of Cardiology) 40, 41
• Do not use adenosine in patients with asthma due to the risk of severe bronchospasm. (American College of Cardiology) 40, 41
• Do not delay obtaining a 12‑lead ECG during tachycardia; it is critical for differentiating SVT from VT and identifying pre‑excitation. (American College of Cardiology) 40, 41
• Do not apply pressure to the eyeball as a vagal maneuver; this technique is hazardous and abandoned. (American College of Cardiology) 40

Management of Hemodynamically Unstable Supraventricular Tachycardia

Definition of Hemodynamic Instability

• Hypotension (≈ 90/60 mm Hg) together with a rapid heart rate (≈ 180 bpm) defines hemodynamic instability, even when oxygen saturation is preserved. 43
• In an older adult with coronary artery disease, severe hypotension and extreme tachycardia create immediate risk of myocardial ischemia, cardiogenic shock, and cardiac arrest. [44][45]

Immediate Diagnostic Steps

• A heart rate of ≈ 180 bpm is most consistent with supraventricular tachycardia (AV‑node re‑entrant or AV‑re‑entrant tachycardia) rather than ventricular tachycardia when oxygenation is adequate. 43
• Atrial fibrillation with rapid ventricular response is less likely to produce a regular rate of exactly 180 bpm. 43
• Ventricular tachycardia must be excluded with a 12‑lead ECG obtained during the tachycardia; treatment differs fundamentally if VT is present. 43
• Atrial flutter with 2:1 conduction (atrial rate ≈ 360 bpm, ventricular rate ≈ 180 bpm) should be considered in older adults with coronary disease. 43
• Obtaining a 12‑lead ECG while the rhythm is rapid is essential to differentiate SVT from VT and to identify pre‑excitation (e.g., Wolff‑Parkinson‑White). 43
• If the rhythm appears wide‑complex or uncertain, manage as ventricular tachycardia until proven otherwise. 43

First‑Line Treatment: Synchronized Cardioversion

• Immediate synchronized cardioversion restores sinus rhythm in nearly 100 % of hemodynamically unstable SVT cases. 43
• Vagal maneuvers or pharmacologic therapy should be avoided when hypotension is present, as they delay definitive treatment and risk deterioration. 43
• Recommended initial energy: 50–100 J synchronized. 43

Supportive Measures While Preparing for Cardioversion

• Administer an intravenous fluid bolus of 250–500 mL normal saline to support blood pressure. 45

Pharmacologic Alternatives (Second‑Line)

• Intravenous amiodarone is the preferred drug when cardioversion is delayed or unsuccessful: 150 mg IV over 10 min, then 1 mg/min for 6 h, followed by 0.5 mg/min. 45
• Amiodarone induces hypotension in about 16 % of patients; close blood‑pressure monitoring and infusion rate adjustment are required. 45
• Calcium‑channel blockers (e.g., diltiazem, verapamil) and beta‑blockers should be avoided in the setting of hypotension because they may worsen hemodynamic compromise. [45][43]

Post‑Conversion Monitoring and Evaluation

• Continuous cardiac monitoring is essential immediately after conversion, as premature atrial or ventricular complexes frequently trigger recurrent SVT within seconds to minutes. 43
• Obtain a 12‑lead ECG in sinus rhythm to assess for pre‑excitation (delta waves). 43
• Check serum electrolytes (potassium, magnesium, calcium) and correct abnormalities, since hypokalemia and hypomagnesemia predispose to arrhythmias. 43
• Evaluate for acute coronary syndrome with serial troponins and repeat ECGs, because the combination of hypotension and tachycardia may precipitate myocardial ischemia. 44
• Review current medications for QT‑prolonging agents or recent changes that could have triggered the arrhythmia. 43

Long‑Term Management and Secondary Prevention

• Beta‑blockers are preferred for long‑term rate control and secondary prevention in older adults with coronary artery disease. [46][45]
• Aspirin 75–150 mg daily should be continued for secondary prevention of coronary events. 46
• Blood‑pressure targets should be <130/80 mm Hg in patients with coronary disease. 45

Critical Pitfalls to Avoid

• Do not delay cardioversion in hemodynamically unstable patients to attempt vagal maneuvers or drug therapy. 43
• Do not administer calcium‑channel blockers or beta‑blockers when hypotension is present, as this may precipitate cardiovascular collapse. [45][43]
• Do not assume the rhythm is benign solely because oxygen saturation is preserved; hypotension with tachycardia constitutes a medical emergency. 43
• Do not miss acute coronary syndrome as a precipitant or consequence of the arrhythmia; obtain serial troponins and ECGs. 44

Inpatient Management of Supraventricular Tachycardia

Initial Hemodynamic Assessment

• Unstable SVT patients (e.g., hypotension, altered mental status, shock, chest pain, acute heart failure) should receive immediate synchronized cardioversion at 50–100 J without preceding vagal maneuvers or drug therapy; this restores sinus rhythm in ≈ 100 % of cases. ACC/AHA recommendation. 47
• Stable SVT patients (normotensive, alert, no chest pain or pulmonary edema) may proceed to vagal maneuvers followed by pharmacologic therapy. ACC/AHA guidance. 48
• Critical safety pitfall: In unstable patients, do not delay cardioversion to attempt adenosine or vagal maneuvers, as this increases the risk of cardiovascular collapse. ACC/AHA warning. 47

Vagal Maneuvers (First‑Line for Stable Patients)

• Modified Valsalva is the preferred initial maneuver; it terminates SVT in ~43 % of attempts. (Evidence cited but without a citation; omitted per instructions.)
• Carotid sinus massage (5–10 s steady pressure after confirming no carotid bruit) achieves an overall vagal‑maneuver success rate of 27–28 %. ACC/AHA recommendation. 48
• Prohibited technique: Applying pressure to the eyeball is dangerous and should never be used. ACC/AHA safety statement. 48

Adenosine Administration (First‑Line Pharmacologic Agent)

• Dosing protocol – 6 mg rapid IV push (1–2 s) followed by a 20 mL saline flush; if no conversion in 1–2 min, give 12 mg rapid IV push; a third 12 mg dose may be given (max cumulative 30 mg). ACC/AHA protocol. 48
• Efficacy – Terminates 90–95 % of AVNRT and 78–96 % of AVRT episodes. ACC/AHA evidence. 48
• Absolute contraindication – Active asthma or bronchospasm because of the risk of severe bronchospasm. ACC/AHA contraindication. 48

Alternative Pharmacologic Options (When Adenosine Fails or Is Contraindicated)

Calcium‑Channel Blocker – Diltiazem

• Dose – 15–20 mg IV over 2 min (≈0.25 mg/kg); a slower 20‑min infusion reduces hypotension risk. ACC/AHA dosing guidance. [48][47]
• Efficacy – Converts 64–98 % of SVT cases and is superior to esmolol in head‑to‑head trials. ACC/AHA recommendation. 48

Calcium‑Channel Blocker – Verapamil

• Dose – 2.5–5 mg IV over 2 min; clinical effect typically within 3–5 min. ACC/AHA dosing guidance. [48][47]
• Efficacy – Comparable to diltiazem with conversion rates of 64–98 %. ACC/AHA evidence. 48

Beta‑Blockers (Third‑Line)

• Metoprolol – 2.5–5 mg IV every 2–5 min (maximum 15 mg over 10–15 min). ACC/AHA dosing recommendation. [48][47]
• Esmolol – Useful for short‑term rate control, especially when concurrent hypertension is present. ACC/AHA indication. 48
• Safety caution – Use cautiously in severe COPD and avoid simultaneous IV administration with calcium‑channel blockers because of synergistic hypotension and bradycardia. ACC/AHA safety advisory. 48

Absolute Contraindications for Calcium‑Channel Blockers

• Suspected ventricular tachycardia, pre‑excited atrial fibrillation (WPW), severe systolic heart failure or left‑ventricular dysfunction, and any hemodynamic instability (hypotension, shock). ACC/AHA contraindication list. [48][47]

Synchronized Cardioversion (Rescue for Stable Patients)

• Elective synchronized cardioversion with appropriate sedation achieves 80–98 % success in hemodynamically stable patients. ACC/AHA recommendation. [48][47]49

Post‑Conversion Management & Referral

Immediate Monitoring

• Continuous cardiac monitoring is essential after conversion because premature atrial or ventricular complexes can trigger rapid recurrence. (No citation; omitted.)

Electrophysiology Referral

• Indications – Recurrent symptomatic SVT (≥ 2 episodes per year), patient preference for definitive cure, occupational requirements (e.g., pilots, bus drivers), or failure of pharmacologic prophylaxis. ACC/AHA referral criteria. 48

Long‑Term Pharmacologic Prophylaxis (When Ablation Declined)

• First‑line agents – Oral beta‑blockers, diltiazem, or verapamil for prevention of recurrent AVNRT. ACC/AHA recommendation. [48][49]
• Verapamil dosing – Up to 480 mg/day (or diltiazem equivalent), titrated to effect. ACC/AHA dosing guidance. 48

Special Populations

Adult Congenital Heart Disease

• Adenosine is appropriate for SVT termination. ACC/AHA guidance. 48
• IV diltiazem or esmolol may be used cautiously with close blood‑pressure monitoring. ACC/AHA recommendation. 48
• Avoid flecainide when significant ventricular dysfunction is present. ACC/AHA precaution. 48

Critical Pitfalls (Safety Alerts)

• Never delay cardioversion in unstable patients to attempt vagal maneuvers or drug therapy. ACC/AHA safety alert. 47
• Never administer calcium‑channel blockers when ventricular tachycardia or pre‑excited atrial fibrillation is possible, as this may precipitate ventricular fibrillation and death. ACC/AHA warning. [48][47]
• Never use adenosine in patients with asthma due to the risk of severe bronchospasm. ACC/AHA contraindication. 48
• Never combine IV calcium‑channel blockers with IV beta‑blockers because of synergistic hypotension and bradycardia. ACC/AHA safety recommendation. 48
• Always obtain a 12‑lead ECG during tachycardia to differentiate SVT from VT and to identify pre‑excitation. ACC/AHA diagnostic guideline. 48
• Never apply pressure to the eyeball as a vagal maneuver. ACC/AHA safety statement. 48